These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38293765)

  • 1. Factors and economic burden of non-severe hypoglycemia among insulin-treated type 2 diabetes patients: a cross-sectional study.
    Kosachunhanun N; Wongsa D; Permsuwan U
    Curr Med Res Opin; 2024 Mar; 40(3):385-393. PubMed ID: 38293765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of severe hypoglycemia in type 2 diabetes.
    Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
    Curr Med Res Opin; 2018 Jan; 34(1):179-186. PubMed ID: 29017368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fear of hypoglycemia and associated factors in hospitalized patients with type 2 diabetes: a cross‑sectional study.
    Huang J; Peng W; Ding S; Xiong S; Liu Z
    Sci Rep; 2022 Nov; 12(1):20338. PubMed ID: 36434039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
    Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
    J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V; Davidson J; Home P; Snyder J; Jellinger P; Dyhr Toft A; Barnett A
    Curr Med Res Opin; 2010 Jul; 26(7):1621-8. PubMed ID: 20429817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
    Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring.
    Gómez AM; Imitola Madero A; Henao Carrillo DC; Rondón M; Muñoz OM; Robledo MA; Rebolledo M; García Jaramillo M; León Vargas F; Umpierrez G
    J Diabetes Sci Technol; 2020 Mar; 14(2):233-239. PubMed ID: 30678495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.
    Meneghini LF; Lee LK; Gupta S; Preblick R
    Diabetes Obes Metab; 2018 May; 20(5):1156-1165. PubMed ID: 29316141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of severe hypoglycemia in type 1 diabetes.
    Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
    Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cross-Sectional study on risk factors for severe hypoglycemia among Insulin-Treated elderly type 2 diabetes Mellitus (T2DM) patients in Singapore.
    Shi Min Ko M; Kit Lee W; Chang Ang L; Goh SY; Mong Bee Y; Ming Teh M
    Diabetes Res Clin Pract; 2022 Mar; 185():109236. PubMed ID: 35131380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and awareness of hypoglycemia in patients with Type 2 Diabetes treated with two or more insulin injections in primary care outpatient clinics.
    Cabré C; Colungo C; Vinagre I; Jansà M; Conget I
    Prim Care Diabetes; 2020 Apr; 14(2):168-172. PubMed ID: 31474469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort.
    van Meijel LA; de Vegt F; Abbink EJ; Rutters F; Schram MT; van der Klauw MM; Wolffenbuttel BHR; Siegelaar S; DeVries JH; Sijbrands EJG; Özcan B; de Valk HW; Silvius B; Schaper N; Stehouwer CDA; Elders PJM; Tack CJ; de Galan BE
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy--a combined analysis of 713 type 2 diabetic patients.
    Seufert J; Brath H; Pscherer S; Borck A; Bramlage P; Siegmund T
    Diabetes Obes Metab; 2014 Mar; 16(3):248-54. PubMed ID: 24033863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers.
    Shi L; Fonseca V; Childs B
    J Diabetes Complications; 2021 Jun; 35(6):107916. PubMed ID: 33836965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network meta-analysis of glucose-lowering drug treatment regimens with the potential risk of hypoglycemia in patients with type 2 diabetes mellitus in terms of glycemic control and severe hypoglycemia.
    Kodama S; Fujihara K; Ishiguro H; Matsubayashi Y; Kitazawa M; Iwanaga M; Yamada T; Kato K; Nakagawa Y; Tanaka S; Shimano H; Sone H
    J Investig Med; 2023 Apr; 71(4):400-410. PubMed ID: 36695427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
    Haldrup S; Lapolla A; Gundgaard J; Wolden ML
    J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.